NCT02564900: Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

NCT02564900
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: Only HER2+ patients (including HER2 low expression) will be eligible for Part 2 of the study
Exclusions: 
https://ClinicalTrials.gov/show/NCT02564900

Comments are closed.

Up ↑